Cargando…

Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients

Whereas positron emission tomography (PET) with the antagonist ligand [(18)F]fallypride reveals the composite of dopamine D2 and D3 receptors in brain, treatment of Parkinson's disease (PD) patients with the D3-prefering agonist pramipexole should result in preferential occupancy in the nucleus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deutschländer, Angela, la Fougère, Christian, Boetzel, Kai, Albert, Nathalie L., Gildehaus, Franz-Josef, Bartenstein, Peter, Xiong, Guoming, Cumming, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925448/ https://www.ncbi.nlm.nih.gov/pubmed/27408789 http://dx.doi.org/10.1016/j.nicl.2016.06.007

Ejemplares similares

Enhanced Taste Recognition Following Subacute Treatment With The Dopamine D2/D3 Receptor Agonist Pramipexole in Healthy Volunteers
por: Kaltenboeck, Alexander, et al.
Publicado: (2022)

Update on the use of pramipexole in the treatment of Parkinson’s disease
por: Constantinescu, Radu
Publicado: (2008)

Dyskinesias and Treatment with Pramipexole in Patients with Parkinson's Disease
por: Piedad, John C. P., et al.
Publicado: (2012)

Pramipexole and its Extended Release Formulation for Parkinson’s Disease
por: Fishman, Paul S.
Publicado: (2011)

Analysis of pramipexole dose–response relationships in Parkinson’s disease
por: Wang, Ying, et al.
Publicado: (2016)

Pramipexole Inhibits Neuronal Apoptosis in Rats with Parkinson's Disease
por: Sun, Yongqi, et al.
Publicado: (2022)

Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D(3 )receptor
por: Joyce, Jeffrey N, et al.
Publicado: (2004)

Beneficial effect of pramipexole for motor function and depression in Parkinson’s disease
por: Kano, Osamu, et al.
Publicado: (2008)

Retracted: Pramipexole Inhibits Neuronal Apoptosis in Rats with Parkinson's Disease
por: Healthcare Engineering, Journal of
Publicado: (2023)

Baseline Perfusion Alterations Due to Acute Application of Quetiapine and Pramipexole in Healthy Adults
por: Michels, Lars, et al.
Publicado: (2016)

Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease
por: Eisenreich, Wolfram, et al.
Publicado: (2010)

Reply: long-term retention rate of pramipexole in the treatment of Parkinson’s disease
por: Arbouw, Maurits E. L., et al.
Publicado: (2009)

Possible effects of pramipexole on neck muscles in a patient with Parkinson's disease
por: Filippi, Roberto, et al.
Publicado: (2014)

Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease()
por: Schlaudraff, Falk, et al.
Publicado: (2014)

Dopamine Dysregulation Syndrome in Parkinson’s Disease Patients with Unsatisfactory Switching from Immediate to Extended Release Pramipexole: A Further Clue to Incentive Sensitization Mechanisms?
por: Solla, Paolo, et al.
Publicado: (2013)

Role and clinical utility of pramipexole extended release in the treatment of early Parkinson’s disease
por: Hametner, Eva-Maria, et al.
Publicado: (2012)

Patient considerations in early management of Parkinson’s disease: focus on extended-release pramipexole
por: Salawu, Fatai Kunle
Publicado: (2012)

Pramipexole-induced antecollis in patients with Parkinson's disease: Two cases and literature review
por: Iijima, Mutsumi, et al.
Publicado: (2015)

Dramatic Response to Pramipexole in Delayed-Onset Parkinsonism from Osmotic Demyelinating Syndrome
por: Han, Steve C., et al.
Publicado: (2020)

Processing speed is related to striatal dopamine transporter availability in Parkinson's disease
por: Vriend, Chris, et al.
Publicado: (2020)

Pramipexole use and the risk of pneumonia
por: Ernst, Pierre, et al.
Publicado: (2012)

Pramipexole: new use for an old drug – the potential use of pramipexole in the treatment of restless legs syndrome
por: Benbir, Gulcin, et al.
Publicado: (2006)

Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients
por: Antonini, Angelo, et al.
Publicado: (2011)

Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Pramipexole in a Patient with Parkinson’s Disease
por: Choi, Yoonjae, et al.
Publicado: (2010)

Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Pramipexole in a Patient with Parkinson’s Disease
por: Choi, Yoonjae, et al.
Publicado: (2011)

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial
por: Schapira, Anthony HV, et al.
Publicado: (2013)

Auditory Musical Hallucinations Associated With Extended-Release Pramipexole in an Elderly Patient With Parkinson's Disease
por: Kataoka, Hiroshi, et al.
Publicado: (2014)

Effects of pramipexole treatment on the α-synuclein content in serum exosomes of Parkinson's disease patients
por: Luo, He-Ting, et al.
Publicado: (2016)

The Efficacy of Pramipexole, a Dopamine Receptor Agonist, as an Adjunctive Treatment in Treatment-Resistant Depression: An Open-Label Trial
por: Hori, Hiroaki, et al.
Publicado: (2012)

Gastrointestinal Symptoms and Dopamine Transporter Asymmetry in Early Parkinson's Disease
por: Murtomäki, Kirsi, et al.
Publicado: (2022)

Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease
por: Caminiti, Silvia Paola, et al.
Publicado: (2017)

Refining diagnosis of Parkinson's disease with deep learning-based interpretation of dopamine transporter imaging
por: Choi, Hongyoon, et al.
Publicado: (2017)

Assessment of synaptic loss in mouse models of β-amyloid and tau pathology using [(18)F]UCB-H PET imaging
por: Vogler, Letizia, et al.
Publicado: (2023)

Burning mouth syndrome responsive to pramipexol
por: Stuginski-Barbosa, J., et al.
Publicado: (2008)

Automatic behavior and communication due to pramipexole
por: Walker, Ruth H.
Publicado: (2016)

Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release
por: Hauser, Robert A., et al.
Publicado: (2014)

Retraction: Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Pramipexole in a Patient with Parkinson’s Disease
Publicado: (2015)

Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease
por: Hauser, R A, et al.
Publicado: (2014)

The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients
por: Faddoul, Lama, et al.
Publicado: (2018)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease
por: Yun, Ji Young, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_asrcn18oeb2meitt1kar5sv0so